Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2023.12.010 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Eleni Gavriilaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department-BMT Unit, G Papanikolaou Hospital, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Neutropenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Loss of microbiota diversity has been clearly associated with poor outcomes in the allogeneic hematopoietic stem cell transplantation setting. However, the choice of the optimal antibiotic prophylaxis during the pre-engraftment phase remains unclear. We designed a prospective randomized study to compare our standard-of-care neutropenia prophylaxis (ciprofloxacin) with rifaximin. We enrolled 38 consecutive adult patients who underwent allogeneic hematopoietic stem cell transplantation setting and were randomly assigned to receive ciprofloxacin (20 patients) or rifaximin (18 patients) at day -1. Pretransplant and transplant characteristics did not differ between groups. Cumulative incidence (CI) of acute graft-vs-host disease grade II to IV and moderate/severe chronic graft-vs-host disease was similar in both groups. With a median follow-up of 13.2 months (range, 6.8-30.2) in surviving patients, the 1-year CI of relapse was 20.8% in ciprofloxacin vs 17.8% in rifaximin (P = .616). Importantly, the 1-year CI of treatment-related mortality was significantly reduced in the ciprofloxacin group (10.2% vs 27.8%, P = .032), leading to higher 1-year overall survival (88.9% vs 74.6%, P = .038). In Cox-regression multivariate analysis, antibiotic prophylaxis remained the only predictor of overall survival, independently of donor type, disease risk index, and moderate/severe chronic graft-vs-host disease. Further studies are needed to assess the effects on microbiota diversity and confirm these outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology Department-BMT Unit, G Papanikolaou Hospital, Thessaloniki, Greece.
- Hematology Department-BMT Unit, Geneva University Hospital, Geneva, Switzerland. Electronic address: eugenialaspa@gmail.com.
- Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Microbiology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Zitieren
APA
Gavriilaki, E., Mallouri, D., Laspa, E., Papakonstantinou, A., Lazaridou, A., Varelas, C., Baldoumi, E., Giannakopoulou, A., Demosthenous, C., Vardi, A., Bousiou, Z., Batsis, I., Gkioula, G., Anagnostopoulos, A., & Sakellari, I. (2024). Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.12.010
Vancouver
Gavriilaki E, Mallouri D, Laspa E, Papakonstantinou A, Lazaridou A, Varelas C, et al. Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2023.12.010
BibTeX
@article{Gavriilaki2024,
author = {Gavriilaki, Eleni and Mallouri, Despina and Laspa, Evgenia and Papakonstantinou, Anna and Lazaridou, Andriana and Varelas, Christos and Baldoumi, Eirini and Giannakopoulou, Angeliki and Demosthenous, Christos and Vardi, Anna and Bousiou, Zoi and Batsis, Ioannis and Gkioula, Georgia and Anagnostopoulos, Achilles and Sakellari, Ioanna},
title = {Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2023.12.010}
}
EUVIMED